Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 6Recruiting 2Not yet recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3Sarcoma 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × surufatinib × Thoracic × Clear all
NCT05509699 2025-08-29

Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Hutchmed

Phase 2 Completed
21 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡